BRC Therapeutics Participates in FDA and EMA Workshop on Botanical Drug Development

BRC Therapeutics announced its participation in the Regulatory Perspectives on Herbal Medicinal/Botanical Drug Product Development workshop, held in Amsterdam on September 28, 2026. The event was a joint session convened by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Dr. Catherine Maher, BRC's Head of Regulatory Affairs, represented the company. The workshop brought together regulators and drug developers to discuss regulatory considerations for botanical drug products intended for medicinal use. Participation was limited, and BRC received an invitation.

The workshop follows recent FDA initiatives aimed at advancing botanical drug development, including a Request for Information seeking public input, to which BRC submitted a contribution. These steps signal regulatory momentum towards clearer pathways for botanical medicines.

BRC Therapeutics is developing multimodal cannabinoid therapeutics for neurological and inflammatory conditions, with multiple prescription-grade products currently in clinical trials. The company aims to contribute to the advancement of botanical drug development and patient access to validated therapies.